Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by RAMMURTI KAMBLE and GEORGE CARRUM.
RAMMURTI KAMBLE
Connection Strength
3.829
GEORGE CARRUM
  1. Neuropathic dermatomes and cutaneous ulceration in patients with chronic GVHD. Bone Marrow Transplant. 2014 Jul; 49(7):986-7.
    View in: PubMed
    Score: 0.477
  2. Acute gout at engraftment following hematopoietic transplantation. Am J Hematol. 2011 Nov; 86(11):961-2.
    View in: PubMed
    Score: 0.398
  3. Human metapneumovirus infection in a hematopoietic transplant recipient. Bone Marrow Transplant. 2007 Oct; 40(7):699-700.
    View in: PubMed
    Score: 0.299
  4. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Sep; 40(6):563-6.
    View in: PubMed
    Score: 0.298
  5. Central nervous system graft-versus-host disease: report of two cases and literature review. Bone Marrow Transplant. 2007 Jan; 39(1):49-52.
    View in: PubMed
    Score: 0.285
  6. Rituximab responsive refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006 Nov; 12(11):1201-2.
    View in: PubMed
    Score: 0.284
  7. Successful mobilization and transplantation of filgrastim mobilized hematopoietic stem cells in sickle cell-hemoglobin C disease. Bone Marrow Transplant. 2006 Jun; 37(11):1065-6.
    View in: PubMed
    Score: 0.276
  8. Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2022 04; 57(4):579-585.
    View in: PubMed
    Score: 0.204
  9. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
    View in: PubMed
    Score: 0.190
  10. Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization. Clin Med Insights Blood Disord. 2018; 11:1179545X18792253.
    View in: PubMed
    Score: 0.161
  11. Voriconazole photosensitivity causes apparent graft-versus-host disease exacerbation. Bone Marrow Transplant. 2019 02; 54(2):323-325.
    View in: PubMed
    Score: 0.160
  12. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014 Feb; 49(2):219-22.
    View in: PubMed
    Score: 0.115
  13. Systemic effects of oral budesonide in hematopoietic transplant: implications of drug interaction with azoles. Bone Marrow Transplant. 2012 Oct; 47(10):1370-1.
    View in: PubMed
    Score: 0.102
  14. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9.
    View in: PubMed
    Score: 0.073
  15. Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2024 Dec; 30(12):1193.e1-1193.e8.
    View in: PubMed
    Score: 0.061
  16. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711.
    View in: PubMed
    Score: 0.052
  17. Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies. Blood Adv. 2021 11 23; 5(22):4630-4633.
    View in: PubMed
    Score: 0.050
  18. Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leuk Lymphoma. 2021 12; 62(13):3256-3263.
    View in: PubMed
    Score: 0.049
  19. Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. Transplant Cell Ther. 2021 09; 27(9):785.e1-785.e6.
    View in: PubMed
    Score: 0.049
  20. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
    View in: PubMed
    Score: 0.049
  21. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554).
    View in: PubMed
    Score: 0.046
  22. In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
    View in: PubMed
    Score: 0.040
  23. Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
    View in: PubMed
    Score: 0.035
  24. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
    View in: PubMed
    Score: 0.029
  25. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6.
    View in: PubMed
    Score: 0.024
  26. Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma. 2010 Apr; 51(4):664-70.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.